Phase 1 safety trial of Filgrastim (r-metHuG-CSF) in non-neutropenic patients with severe community-acquired pneumonia  by deBoisblanc, B.P. et al.
RESPIRATORY MEDICINE (1997) 91, 387-394 
Original Articles 
Phase 1 safety trial of Filgrastim (r-metHuG-CSF) in 
non-neutropenic patients with severe 
community-acquired pneumonia 
B. P. DEBOISBLANC~, C. M. MASON*, J. ANDRESEN~, E. LOGAN+, M. B. BEAR+, 
S. JOHNSON+, J. SHELLITO-, W. R. SUMMER- AND S. NELSON- 
-Section of Pulmonary Critical Care Medicine, Department of Medicine, Louisiana State University 
Medical School, New Orleans, LA, U.S.A. 
‘Amgen inc., Clinical Development, Thousand Oaks, CA, U.S.A. 
The objectives of the present study were to: (1) evaluate the safety of Filgrastim therapy in non- 
neutropenic patients with severe community-acquired pneumonia; (2) determine the absolute neutrophil 
count (ANC) response to various dosages of Filgrastim in non-neutropenic patients with active infection; 
and (3) describe the impact of therapy with Filgrastim in combination with antibiotics on selected 
pneumonia-related clinical parameters. 
The study design was an open-label, dose-ranging, clinical trial, set in the General Clinical Research 
Unit of a large, public community hospital. The study population consisted of 30 patients who had 
presented to the Emergency Department with severe, community-acquired pneumonia. 
One of five dosages (75, 150, 300, 450 or 600 pug day - ‘) of Filgrastim (r-metHuG-CSF) was given 
subcutaneously daily for 10 days, until discharge or until the absolute neutrophil count >75 x lo9 l- I, 
whichever was earlier. Vital signs, pulse oximetry, arterial blood gases, daily complete blood counts with 
differential, serum chemistries, coagulation profiles, electrocardiograms, chest radiographs, plasma 
G-CSF concentrations and duration of hospitalization were measured. 
There was no evidence of Filgrastim-related lung injury or evidence of extra-pulmonary toxicity. There 
was no apparent dose-response effect of Filgrastim on pneumonia-related clinical variables. Dosages of 
Filgrastim between 150 and 6OOpg day- ’ had similar effects on increasing the ANC. 
Filgrastim appeared to be safe in non-neutropenic patients with severe, community-acquired pneu- 
monia when given in dosages of 75-600,ug day - ’ in combination with appropriate antibiotic therapy. 
Further study is needed to determine the effect of Filgrastim on morbidity, mortality and duration of 
symptoms in this patient population. 
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Introduction 
In spite of advances in antibiotic therapy and 
improved life-support measures, pneumonia and 
influenza remain the sixth leading cause of death in 
the United States, and the most common cause of 
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death from infectious disease (1). The mortality of 
patients who require hospitalization for pneumonia 
typically ranges from 10 to 25%. However, in the 
subset of patients who require admission to an inten- 
sive care unit (ICU), mortality rates have been 
reported to range from 25 to 93% (24). Most 
patients who die have well-recognized co-morbid risk 
factors, such as advanced age, chronic lung disease, 
diabetes or alcoholism. 
While the pathogenesis of bacterial pneumonia is 
not fully understood, it is thought to result from 
colonization of the posterior pharynx with pathogenic 
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bacteria and subsequent micro-aspiration of these 
bacteria into the lower respiratory tract. If host 
respiratory-defence mechanisms, such as cough, 
mucociliary elevator action or phagocytic function, 
are inadequate, if the inoculum is large, or if the 
bacteria are particularly virulent, pneumonia may 
result. 
Granulocyte colony-stimulating factor (G-CSF) is 
a growth factor produced by monocytes, fibroblasts 
and endothelial cells. It has at least three separate 
roles in vitro: a direct influence upon proliferation and 
development of neutrophil progenitor cells (5-8); 
stimulation or proliferation and functional activation 
of more mature cells of the neutrophil lineage (9,lO); 
and ability to synergize with other haematopoietic 
growth factors (11,12). Non-glycosylated, recom- 
binant human G-CSF (rHuG-CSF, Filgrastim) has 
been cloned and expressed, and has been approved by 
the Food and Drug Administration (FDA) (U.S.A.) 
and other regulatory agencies to decrease the inci- 
dence and duration of severe neutropenia induced by 
cytotoxic chemotherapy for solid tumours (13-l 6), 
and for conditioning regimens for autologous bone 
marrow transplantation in patients with non-myeloid 
malignancies (17). Filgrastim is also approved for the 
treatment of severe chronic neutropenia (18) and 
for haematopoietic reconstitution following bone 
marrow transplantation (19). It has been shown to 
reduce the incidence of fever associated with neutro- 
penia, the incidence of culture-confirmed infections, 
the total number of days of treatment with intra- 
venous antibiotics, and the total number of days of 
hospitalization (20-22). 
In non-neutropenic animal models of pneumonia, 
treatment with Filgrastim improved bacterial clear- 
ance from the lung and reduced mortality (23). In 
a mouse model, Filgrastim administered from 24 h 
before bacterial challenge to 3 days after challenge 
was found to improve survival in splenectomized mice 
but not in sham-operated mice exposed to Strepto- 
coccus pneumoniae (24). A recently published study 
examined the use of Filgrastim, given with antibiotics, 
on morbidity and mortality in animals with pneumo- 
nia and sepsis (25). Rabbits were infected with 
penicillin-sensitive, Gram-negative bacteria and then 
randomized to receive penicillin with placebo or 6.5- 
8pg kg-’ day-’ Filgrastim for 5 days. The rabbits 
treated with Filgrastim had a significant increase in 
the number of neutrophils by Day 4 of the study 
compared with rabbits treated with placebo, and 
there was a trend towards improved survival in the 
Filgrastim-treated animals, with most of the survival 
benefit seen in the first 24 h of treatment. 
The present dose-ranging study was designed to 
evaluate the safety of Filgrastim therapy in non- 
TABLE 1. Risk factors for severe disease 
Age 60 years 
Pre-existing chronic illness, such as COPD, diabetes 
mellitus or alcoholism 
Respiratory rate ~25 and ~40 breaths min - ’ 
Hypoxia (PaO, on room air ~65 mmHg) 
Relative leukopenia (WBC 3-6 x lo9 1 - i) 
Blood urea nitrogen >20 mg dl- ’ in the absence of 
chronic renal disease 
Splenectomy or prior splenic radiation 
Chronic steroid therapy 
Multilobar infiltrates on chest radiograph 
COPD, chronic obstructive pulmonary disease. 
neutropenic patients with severe community-acquired 
pneumonia. As neutrophils had been reported to play 
a potential role in the pathogenesis of the acute 
respiratory distress syndrome (ARDS) (26), the 
potential of Filgrastim-induced neutrophilia to aggra- 
vate pulmonary inflammation and injury was of 
primary interest. Secondary objectives were to deter- 
mine the absolute neutrophil count (ANC) response 
to various dosages of Filgrastim in non-neutropenic 
patients with active infection, and to describe the 
impact of therapy with Filgrastim in combination 
with antibiotics on selected pneumonia-related 
clinical parameters. 
Methods 
PATIENTS 
The study was approved by the Institutional Review 
Board of Louisiana State University Medical 
Center and was conducted in the General Clinical 
Research Center of Charity Hospital of Louisiana. 
Community-acquired pneumonia was defined by the 
presence of a new productive cough or changes in a 
chronic cough, core body temperature 238~3°C or 
~36°C and a new infiltrate on chest radiography 
that is compatible with the diagnosis of pneumonia. 
Patients who required hospitalization for the treat- 
ment of community-acquired pneumonia were eligible 
to be enrolled in this trial if two or more risk factors 
for adverse outcome (Table 1) were present. Patients 
were excluded from the trial if any of the exclusion 
criteria (Table 2) were present. Written informed 
consent was obtained from all patients enrolled. 
STUDY DESIGN 
Sputum and blood cultures were obtained prior to the 
administration of cefuroxime 1.5 g intravenously 
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TABLE 2. Exclusion criteria 
Age < 18 years 
Pregnant 
Allergy to penicillin, cephalosporins or Escherchia coli-derived products 
Need for >50% supplemental oxygen, need for ventilary assistance upon admission, or 
diagnosis of ARDS 
Suspected tuberculosis, post-obstructive pneumonia or non-bacterial pneumonia 
Haematologic abnormality (platelet count < 10 x lo9 l- ‘, ANC < 1.5 x lo9 l- ’ or 
>40 x lo9 l- ‘, or any haematologic malignancy 
Cardiac abnormalities (uncontrolled hypertension with diastolic blood pressure 
> 115 mmHg, symptomatic cardiac arrhythmias, unstable angina, or NYHA Class IV 
congestive heart failure) 
Shock, acute hepatic or renal failure, disseminated intravascular coagulation (DIC), or 
respiratory failure (PaO,lfiO, <200) 
Established diagnosis of HIV infection 
Previous treatment with cytotoxic chemotherapy or radiotherapy 
ARDS, adult respiratory distress syndrome; ANC, absolute neutrophil count. 
(i.v.) every 8 h for at least 48 h. Groups of five to nine 
patients were given one of five dosages of Filgrastim 
(75, 150, 300, 450 or 6OOpg day- ‘) subcutaneously 
(SC) for a maximum of 10 days or until an ANC 
>75 x 10’ l- ‘, if earlier. The first dose of Filgrastim 
was given on the day of hospitalization regardless of 
the time, but subsequent doses were given daily at 
9 am. Antibiotics were switched to cefuroxime 
250 mg orally (p.0.) twice daily if all the following 
criteria were met: core body temperature <37.8”C, 
respiratory rate ~20 min - ‘, chest radiograph stable 
or improved, and ability to tolerate oral medication. 
No antipyretics were given but propoxyphene was 
allowed for analgesia. 
LABORATORY TESTS AND CLINICAL 
OBSERVATIONS 
Throughout the study observation, patients were 
monitored with vital signs every 4 h and daily symp- 
tom assessments. Continuous pulse oximetry was 
performed for the first 72 h. Arterial blood gases were 
obtained at baseline and then as indicated. Severity of 
illness was measured at baseline and intermittently 
using the APACHE II scoring system. Daily complete 
blood counts with ANC count were obtained before 
administration of Filgrastim and serum chemistries 
and coagulation profiles were drawn weekly. Chest 
radiographs were obtained every other day and evalu- 
ated by a staff pulmonologist for changes from base- 
line values. At baseline and every morning before 
administration of Filgrastim, a blood sample was 
drawn in an ethylenediaminetetraacetic acid (EDTA)- 
coated vacuum tube for determination of plasma 
G-CSF concentration. These blood samples were 
centrifuged, frozen in cryovials at - 70°C and 
shipped to Amgen (Thousand Oaks, CA, U.S.A.) 
for analysis. Electrocardiograms (ECGs) were ob- 
tained at baseline and then periodically thereafter as 
clinically relevant. 
The duration of hospitalization was defined as the 
time from admission until the time that discharge 
eligibility criteria were met. For protocol purposes, a 
patient was considered eligible for hospital discharge 
once his or her constitutional symptoms were mild or 
resolved, he or she could tolerate oral diet and 
antibiotics, core body temperature was 137.K for 
48 h, and there was no growth on follow-up blood 
cultures if bacteraemic. Outpatient follow-up exams 
and chest radiographs were obtained 2 weeks and 
4 weeks after discharge. 
ADVERSE EVENTS 
All adverse events occurring during the 2-week period 
following presentation were noted for severity and 
relationship to study drug according to the World 
Health Organization (WHO) adverse events standard 
grading score (27). 
STUDY DRUG 
The rHuG-CSF used in this study was Filgrastim 
(NEUPOGEN’“‘), a non-glycosylated product pro- 
duced by recombinant DNA techniques using E. coli. 
The Filgrastim was supplied by the manufacturer 
(Amgen Inc., Thousand Oaks, CA, U.S.A.). 
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TABLE 3. Demographic data of study patients 
Dosage Age Sex Apache II Score 
(,ug day - ‘) Median (range) M/F Median (range) 
75 40 (26-73) 5/l 10 (8-18) 
150 41 (35-53) 4/l 8 (5-l 3) 
300 49 (30-65) 7/2 9 (6-22) 
450 42 (34-62) 312 (4-14) 
600 40 (20-49) 2/3 
1; 
(6-l 3) 
STATISTICAL ANALYSIS 
Due to the small number of patients (n=30), the 
primary focus was only descriptive statistics of central 
tendency and dispersion categorized by dosage group 
and time were done. No inferential statistical analyses 
were done. 
Results 
PATIENTS 
Thirty patients meeting the community-acquired 
pneumonia case definition were enrolled in the study. 
A summary of the demographic data of the treatment 
groups including median APACHE II scores is given 
in Table 3. Twenty-nine patients completed study- 
drug administration through Day 10 or hospital 
discharge. One patient was removed from the study 
on Day 3 when it was determined that his symptoms 
were not due to community-acquired pneumonia, but 
were cardiac in origin. Twenty-three of 29 patients 
(79%) completed one of two post-discharge follow-up 
visits, and 21 patients (72%) completed both. There 
were no on-study deaths. Twenty-one patients (70%) 
were evaluable for the assessment of efficacy of 
Filgrastim dosing and ANC response, and 30 patients 
were evaluable for safety analysis. 
LABORATORY TESTS AND CLINICAL 
OBSERVATIONS 
Five of the 30 patients were bacteraemic, three in the 
75,ug day-’ group and one each in the 300 and 
600 ,ug day - ’ groups. Of the blood cultures from the 
bacteraemic patients, four grew S. pneumoniae and 
one grew Salmonella enteritidis. An additional seven 
patients had sputum cultures positive for a respirat- 
ory pathogen: two S. pneumoniae, four Hemophilus 
influenzae and one Staphylococcus aureus. One 
patient presented with a pleural effusion which was 
Filgrast 
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im dosage (pg day-’ 
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FIG. 1. The temporal relationship between the 
median PaO,lfiO, ratios and Filgrastim dosage. 
‘Baseline’ refers to the value obtained immediately 
before the first dose of Filgrastim, ‘On Filgrastim’ 
(hatched bars) refers to the worst value obtained 
during any subsequent day that a dose of Filgrastim 
was administered, and ‘Off Filgrastim’ (open bars) 
refers to the worst value obtained during any study 
day after Filgrastim was stopped. The numbers of 
patient values in each group appear above the bars. 
subsequently determined to be a polymicrobial 
empyema. Surgical decortication was required for 
resolution. The patient with S. enteritidis bacteraemia 
was determined to be HIV positive after enrollment. 
One patient was also diagnosed to have Legionella 
infection as diagnosed by a positive direct fluorescent 
antibody (DFA). 
Oxygenation remained normal or improved in 
most patients, irrespective of Filgrastim dosage. The 
temporal relationship between the PaO,/fiO, and 
Filgrastim dosage is shown in Fig. 1. There was little 
variation in the median values of systolic and diasto- 
lic blood pressure, pulse rate and respiratory rate 
during the study. Median core body temperature 
decreased from approximately 39 to 37°C by hospital 
discharge. 
The median duration for all patients for fever was 
4 days; for i.v. antibiotic treatment, 6 days; for 
Filgrastim treatment, 7 days; and for hospitalization, 
8 days. There were no clear patterns of dose response 
in these variables. Within each dosage group, the 
median duration of Filgrastim treatment differed 
from the median duration of i.v. antibiotic use and 
hospitalization by no more than 2 days (Fig. 2). 
Figure 3 illustrates the median daily ANC for the 
five dosage groups. The 75,ug day- ’ dose had the 
smallest impact on the ANC, and a relationship 
between dosage and ANC and dosage and peak ANC 
was not established. The median percent change over 
baseline ANC values was 128, 209, 287, 309 and 
194% for the 75, 150, 300, 450 and 600 ,ug day - ’ 
groups, respectively. The highest ANC response was 
101 x lo9 1 - ’ which occurred on Day 4, 1 day before 
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Fever i.v. Antibiotics Filgrastim Hospitalization 
FIG. 2. The median number of days of fever (>37.8”C), intravenous antibiotics, Filgrastim treatment and 
hospitalization are shown for the five treatment groups. Hatched bars, 75 pg day - ‘; solid bars, 150 pg day - ‘; 
shaded bars, 300 ,ug day - ‘; open bars, 450 ,ug day - ‘; cross-hatched bars, 600 ,ug day - ’ 
discharge, in a 53-year-old man in the 300,~~g day - ’ malaise) improved in all patients during the study. 
group. This patient was severely ill on presentation Analyses of ECGs were unchanged from baseline and 
with an APACHE II score of 22. showed no relationship to Filgrastim dosage. 
With the exception of differential leukocyte shifts, 
there was no apparent WHO toxicity shift of two or 
more grades in blood chemistries, haematology, 
coagulation or urinalysis. While receiving Filgrastim, 
14 patients (47%) had increases in monocyte counts, 
13 (43%) had increases in basophil counts, and 12 
(40%) had increases in eosinophil counts that resulted 
in WHO toxicity shifts of two grades or more. 
The median daily G-CSF plasma concentrations 
were independent of the dosage of Filgrastim (Fig. 4). 
Concentrations tended to decrease from the day of 
admission to nearly undetectable levels by discharge, 
regardless of continuation or cessation of Filgrastim. 
There was no relationship between Filgrastim dos- 
age and the rate of radiographic resolution. The 
median time to resolution of the radiographic abnor- 
malities was 12.5 days (range 3-22 days). Pneumonia- 
related symptoms (i.e. fever, cough, chest pain and 
There were three noteworthy protocol violations: 
three patients in the 150 pug day - ’ group received 
acetaminophen during the study, although this was 
prohibited by the protocol. All patients received at 
least two doses of Filgrastim and were evaluable for 
analyses of safety, but only 21 patients received >5 
days of Filgrastim and were therefore appropriate for 
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FIG. 3. Median absolute neutrophil counts (ANC) 
are shown for the five dosage groups. The ‘Baseline 
ANC’ was measured at the time of presentation 
before the first dose of Filgrastim. The ‘Peak ANC’ 
was the highest value obtained after starting 
Filgrastim. The ‘Day of Peak’ was measured by 
counting the day of presentation as Day 1. Hatched 
bars, 75 ,ug day ~ ‘; solid bars, 150 pug day - ‘; shaded 
bars, 300 ,ug day ~ ‘; open bars, 45Opg day - ‘; cross- 
hatched bars, 600 ,ug day - ‘. 
12000> 
1 
6 8 10 12 
Day 
FIG. 4. Median daily plasma concentrations of 
G-CSF for the five dosage groups are shown. These 
blood samples were obtained before each Filgrastim 
dose administered. There appeared to be no corre- 
lation between Filgrastim dosage and the plasma 
G-CSF concentration. Concentrations tended to fall 
after admission even in patients continuing to 
receive Filgrastim. ~ .. -, 75 yg day - ‘; -, 
150,ugdayyI;---, 300,ugday-‘; ..., 
450,ugdayy’; p-p1 600,ugdayy’. 
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analyses of the dose-response relationship between 
Filgrastim and ANC. 
Discussion 
Preclinical investigations of Filgrastim have repeat- 
edly shown it to be effective in enhancing host 
defences against bacterial challenges in several non- 
neutropenic models of sepsis, pneumonia and soft- 
tissue infection (23,28). In patients, many of these 
infectious conditions are also risk factors for ARDS. 
The lung is normally one of the major sites of 
sequestration for non-circulating neutrophils (26) 
and neutrophils can be detected in large numbers in 
the interstitium and air spaces during biopsy as well 
as in the bronchoalveolar lavage fluid of patients with 
ARDS. As activated neutrophils have been impli- 
cated in the pathogenesis of microvascular injury in 
the lung, there has been concern regarding the poten- 
tial of Filgrastim to potentiate lung inflammation 
(29). Filgrastim not only increases the number of 
neutrophils in the pulmonary capillaries but also 
upregulates the expression of the surface receptors 
CD1 lb and CD1 lc, and primes neutrophils for 
chemotaxis and oxygen-radical production (30,31). 
Despite this concern, the reported incidence of 
ARDS in cancer patients receiving Filgrastim has 
only been 0.02%, and nearly all these cases have 
occurred in patients with underlying risk factors for 
ARDS, such as sepsis (Amgen, data on file). Further- 
more, Kanazawa et al. (32) have shown that recom- 
binant G-CSF pretreatment attenuated the lung 
injury induced by intravenous endotoxin in guinea 
pigs, and Koizumi et al. (33) have shown that recom- 
binant G-CSF does not worsen endotoxin-induced 
lung injury in sheep. Fink et al. (34) have made a 
similar observation in pigs. 
This current trial demonstrated the safety and 
feasibility of combining exogenous G-CSF therapy 
(Filgrastim) with antibiotics in the treatment of pneu- 
monia in a group of patients with risk factors for 
ARDS. The degree of blood neutrophilia induced by 
Filgrastim therapy was well tolerated in the patients, 
and no signs or symptoms of pulmonary toxicity were 
observed, nor were there any cases of ARDS. In 
contrast, Terashima et al. (35) have shown that 
recombinant G-CSF can potentiate lung injury 
induced by intratracheal endotoxin in neutropenic 
guinea pigs. Similarly, King et al. (29) have shown 
that Filgrastim can potentiate experimental lung 
injury induced by alpha naphthylthiourea (ANTU) 
and hydrochloric acid (HCl). 
Although pneumonia is the major predisposing 
factor to ARDS in 2040% of cases (36), the apparent 
safety of Filgrastim in this high-risk population is 
conjectured to be related to beneficial effects on 
pulmonary host defences. Infection, and the host 
responses to infection, are major aetiological factors 
responsible for the induction and perpetuation of 
lung injury in ARDS and multisystem organ failure. 
The host response to infection may be a more critical 
determinant of the outcome of sepsis and ARDS than 
the original inciting stimulus (37). If Filgrastim 
speeds bacterial clearance from the lung, then treated 
patients could, theoretically, have less pulmonary 
inflammation and a lower risk of ARDS than non- 
treated patients. 
Although all the patients in this study had risk 
factors for adverse outcomes, patients with evidence 
of organ failure at presentation were intentionally 
excluded because of concerns about differentiating 
between drug-related and disease-related adverse 
events. It remains possible that proliferation and 
activation of neutrophils by Filgrastim in a patient 
with pre-existing ARDS could potentiate lung injury, 
but the answer to this concern must await further 
clinical investigation, 
Conclusions 
Exogenous G-CSF administration, in the form of 
Filgrastim, appeared to be safe in non-neutropenic 
patients with severe community-acquired pneumonia 
when given in dosages of 75-600 ,ug day - ’ in combi- 
nation with appropriate antibiotic therapy. There 
was no evidence of Filgrastim-related lung injury and 
no apparent dose-response effect of Filgrastim on 
pneumonia-related clinical variables. Dosages of 
Filgrastim between 150 and 600 ,ug day - ’ had similar 
effects on ANC. Further study is needed to determine 
the effect of Filgrastim on morbidity, mortality and 
duration of symptoms in patients with severe 
community-acquired pneumonia. 
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